Company Overview and News

 
Altra Industrial Motion Corp. to Host Conference Call on First Quarter 2018 Financial Results

2018-04-06 globenewswire
BRAINTREE, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- Altra Industrial Motion Corp. (Nasdaq:AIMC), a global manufacturer and marketer of electromechanical power transmission and motion control products, intends to release unaudited financial results for the first quarter of 2018 before the market opens on Friday, April 27, 2018.
Upvote Downvote

 
AIMC / Altra Industrial Motion Corp. 425 (Prospectus)

2018-03-23 sec.gov
425 Filed by Altra Industrial Motion Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934
Upvote Downvote

 
AIMC / Altra Industrial Motion Corp. DEF 14A

2018-03-23 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
AIMC / Altra Industrial Motion Corp. 425 (Prospectus)

2018-03-20 sec.gov
425 Filed by Altra Industrial Motion Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934
Upvote Downvote

 
Fortive Accelerating Its Transformation Process

2018-03-20 seekingalpha
Fortive is looking to accelerate its transformation process, selling almost all of its A&S business and looking to reinvest in more software and service-driven businesses.
Upvote Downvote

 
Top Stock Reports for Charter Communications, Mondelez & Halliburton

2018-03-14 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Charter Communications (CHTR), Mondelez (MDLZ) and Halliburton (HAL). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Upvote Downvote

 
AIMC / Altra Industrial Motion Corp. 8-K (Current Report)

2018-03-09 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
Upvote Downvote

 
AIMC / Altra Industrial Motion Corp. 8-K (Prospectus)

2018-03-09 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
Upvote Downvote

 
Altra Industrial to Collaborate With Fortive's A&S Platform

2018-03-09 zacks
Altra Industrial Motion Corp. (AIMC - Free Report) recently signed a definite agreement with Fortive Corporation (FTV - Free Report) in order to merge with the automation and specialty (A&S) platform of the latter. This $3-billion deal will integrate Altra Industrial with four operating businesses of Fortive and not impose any tax burden over the companies’ shareholders. Fortive Corporation’s A&S platform includes premium brands such as Portescap, Kollmorgen, Jacobs Vehicle Systems and Thomson.
Upvote Downvote

 
AIMC / Altra Industrial Motion Corp. 425 (Prospectus)

2018-03-08 sec.gov
425 Filed by Altra Industrial Motion Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Altra Industrial Motion Corp (Commission File No. 001-33209) March 8, 2018 Dear Valued Business Partner:
Upvote Downvote

 
AIMC / Altra Industrial Motion Corp. 425 (Prospectus)

2018-03-08 sec.gov
425 Filed by Altra Industrial Motion Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Altra Industrial Motion Corp (Commission File No. 001-33209) March 8, 2018 Dear Valued Customer:
Upvote Downvote

 
Altra Industrial to Buy Four Fortive A&S Assets by 2018-End

2018-03-08 zacks
Altra Industrial Motion Corporation (AIMC - Free Report) announced yesterday that it has agreed to combine its operations with four companies of Automation and Specialty business of Fortive Corporation (FTV - Free Report) . The transaction — structured to be tax-free for the shareholders of the two companies — is roughly valued at $3 billion. Fortive Corporation’s Automation and Specialty (Fortive A&S) is a business platform for the company’s Industrial Technologies segment.
Upvote Downvote

 
Fortive Sells Automation Businesses To Altra

2018-03-08 seekingalpha
The deal is complicated, and its final shape is subject to a Tax Court ruling, but it will result in Fortive shareholders owning 54.4% of the ‘new’ Altra.
Upvote Downvote

 
AIMC / Altra Industrial Motion Corp. 425 (Prospectus)

2018-03-07 sec.gov
425 Filed by Altra Industrial Motion Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Altra Industrial Motion Corp (Commission File No. 001-33209) March 7, 2018 Dear Fellow Altra Employees:
Upvote Downvote

 
AIMC / Altra Industrial Motion Corp. 425 (Prospectus)

2018-03-07 sec.gov
425 Filed by Altra Industrial Motion Corp. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Altra Industrial Motion Corp (Commission File No. 001-33209) 1. What was announced
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 02208R106